Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised, Double-Blind, Controlled Phase 3 Trial to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in Healthy HIV Unexposed (HU) and HIV Exposed Uninfected (HEU) Newborns in Tuberculosis-Endemic Regions of Sub-Saharan Africa

NCT04975178 is registered in ClinicalTrials.gov with Biofabri, S.L as lead sponsor.

NCT NCT04975178
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04975178 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised, Double-Blind, Controlled Phase 3 Trial to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in Healthy HIV Unexposed (HU) and HIV Exposed Uninfected (HEU) Newborns in Tuberculosis-Endemic Regions of Sub-Saharan Africa
Lead sponsor
Biofabri, S.L
Phase
Phase 3
Overall status
Recruiting
Start date
October 17, 2022
Completion date
February 28, 2029
Enrollment
7,120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis